Ion Exchange (India) Ltd
Ion Exchange (India) Ltd Q1 FY27 Results & Concall Highlights: Revenue, Margins & Order Book
Q1 FY27 earnings call: what management guided on revenue, margins and order book.
What the Q1 FY27 call signalled
2 of 4 strong
Not discussed on this call: fundraise.
The short version
Expect 20% year-on-year consolidated operating income growth (INR 701 crores in Q1 FY27). Company expects a clear path to restoring double-digit profitability over time, despite near-term pressures from legacy projects and geopolitical factors.
From Ion Exchange (India) Ltd's Q1 FY27 earnings-call transcript · updated 26 Aug 2026.
Revenue & Sales Performance
- Expect 20% year-on-year consolidated operating income growth (INR 701 crores in Q1 FY27).
- Specialty chemicals segment revenue projected to increase substantially, with Roha plant utilization and capacity expansions driving growth (potential 50% increase over next 2 years).
- Resin capacity expected to expand up to 5x through Roha and Ankleshwar expansions, targeting a larger global market share.
- Treatment solutions segment focused on higher-value, advanced technology projects like resource recovery, hydrogen, ultra-pure water, and lithium extraction for medium to long-term growth.
- Lifecycle services and industrial products segments showing healthy growth, with lifecycle services growing 28% YoY and industrial products by 14% YoY.
- New contracts (e.g., Hyundai, Petroleum Development Oman) and geographic expansion, especially in North America and overseas markets, expected to boost revenues.
- Bid pipeline strong at INR 9,777 crores, indicating healthy future order inflows.
- Strategic focus on repeatable, less capital-intensive business models like O&M and BOO/BOOT expected to improve revenue predictability.
Profitability & Margins
See what Ion Exchange (India) Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Significant capacity expansion is underway at the Roha and Ankleshwar plants, aiming for approximately 5x the original resin capacity post expansion and de-bottlenecking.
- Phase I (Roha expansion) will double resin capacity; Phase II along with de-bottlenecking will reach 5x total output.
- Investment focus on advanced technologies in the treatment solutions business, including resource recovery, water electrolysis, lithium extraction, ultra-pure water, and high-purity water solutions.
- Strategic investments to strengthen presence in global markets, such as obtaining WQA certification for Americas market and appointing regional leadership across Americas, Asia Pacific, Middle East Africa, and Europe.
- Focus on asset-light models in BOT/BOOT projects, balancing capital intensity and better margin profiles.
- Capital allocation cautious, selective approach in project bidding to manage exposure and ensure profitability.
- Ongoing investments in resins, membranes (including new plants), and specialty chemicals portfolios to drive growth.
Top-ranked in Other Utilities
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Ion Exchange (India) Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- As of June 2026, the total order backlog was approximately INR 2,473 crores.
- The unexecuted portion of the UP government-driven project is around 11% of this backlog.
- A significant part of a large legacy project (excluding UP) is behind completion, with a sizable portion still remaining.
- Management expects a significant part of the large legacy project's work to be completed in the financial year 2027, but full closure may span into the next financial year, due to funding flows.
- Newer, more profitable projects like Hyundai contract are being added to offset legacy project impacts.
- Overall, the company remains fully mobilized and focused on execution but is cautious about increasing receivables without assured fund inflows.
Ion Exchange (India) Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹863 Cr, net profit ₹24 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Ion Exchange (India) Ltd's management said in earlier quarters
Others in Other Utilities this season
- Z-Tech (India) Ltd (Q1 FY27)
Total inquiry funnel across all businesses (Parks, Geotech, Water): ~INR 1,500+ crores. Key concall takeaways from Z-Tech (India) Ltd's Q1 FY27 earnings call…
- EMS Ltd (Q1 FY27)
950 crores for FY’27, reflecting a growth of about 50% compared to the previous year. Key concall takeaways from EMS Ltd's Q1 FY27 earnings call — and how it…
- Refex Industries Ltd (Q1 FY27)
30-35% (Page 7). Key concall takeaways from Refex Industries's Q1 FY27 earnings call — and how it ranks against sector peers.
- Enviro Infra Engineers Ltd (Q1 FY27)
2,700 crores if execution exceeds. Key concall takeaways from Enviro Infra Engineers Ltd's Q1 FY27 earnings call — and how it ranks against sector peers.
Frequently Asked Questions
What were Ion Exchange (India) Ltd Q1 FY27 results?
Expect 20% year-on-year consolidated operating income growth (INR 701 crores in Q1 FY27). Company expects a clear path to restoring double-digit profitability over time, despite near-term pressures from legacy projects and geopolitical factors.
What is Ion Exchange (India) Ltd share price analysis?
Ion Exchange (India) Ltd currently shows a below-average growth signal. The stock trades at a P/E of 49.1 with a market cap of ₹5,407 Cr. Investors should review the full earnings analysis for detailed insights.
Is Ion Exchange (India) Ltd planning capital expenditure?
Significant capacity expansion is underway at the Roha and Ankleshwar plants, aiming for approximately 5x the original resin capacity post expansion and de-bottlenecking.
Keep Ion Exchange (India) Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.